Comparative Pharmacology
Head-to-head clinical analysis: BILDYOS versus STEGLUJAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BILDYOS versus STEGLUJAN.
BILDYOS vs STEGLUJAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BILDYOS (pemigatinib) is a selective, potent, oral inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, and 3. It binds to the ATP-binding pocket of FGFR kinases, inhibiting autophosphorylation and downstream signaling, thereby reducing proliferation and survival of tumor cells with FGFR alterations.
STEGLUJAN is a combination of ertugliflozin and sitagliptin. Ertugliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), enhancing insulin secretion and reducing glucagon secretion.
Adults: 20 mg orally once daily.
Initial: 5 mg/100 mg orally once daily; increase dose based on glycemic response up to 15 mg/100 mg.
None Documented
None Documented
Approximately 24 hours at steady state; supports once-daily dosing.
Terminal elimination half-life is 12–15 hours (mean 13.5 h) in patients with normal renal function; approximately 1.5- to 2-fold longer in moderate renal impairment (eGFR 30–59 mL/min) and up to 3-fold longer in severe renal impairment (eGFR <30 mL/min), necessitating dose reduction.
Primarily biliary/fecal (unchanged drug and metabolites), approximately 90%; renal excretion accounts for less than 10% as unchanged drug and conjugates.
Approximately 70% of an absorbed dose is excreted in the urine (30% as unchanged steglujan, 40% as its active glucuronide metabolite), and 30% is excreted in the feces (primarily as metabolites and unchanged drug via biliary secretion).
Category C
Category C
SGLT2 Inhibitor/Biguanide Combination Antidiabetic
SGLT2 Inhibitor